|
1) |
Nag S, Beyer D, Friedland J, et al. The American Brachytherapy Society(ABS)recommendation for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol. Biol Phys. 1999;44(4):789-99. |
2) |
Nag S, Bice W, DeWyngaert K, et al. The American Brachytherapy Society recommendation for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol phys. 2000;46(1):221-30. |
3) |
Stock RG, Stone NN, Tabert A, et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41(1):101-8. |
4) |
Kollmeier MA, Stock RG, Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up:importance of patient selection and implant quality. Int. J. Radiat Oncol Biol Phys. 2003;57(3):645-53. |
5) |
Waterman MF, et al. Is it necessary to eliminate the posterior dose margin in prostate brachytherapy to achieve an acceptable low risk of late rectal morbidity? Int J Radiat Oncol Biol Phys. 2003;57(1):293-9. |